Bravelle (urofollitropin) / Ferring - LARVOL DELTA

How FSH and LH analogs affect fertility hormone results? (PubMed, Medicine (Baltimore)) - "The effects of urine-derived (menotropin and urofollitropin) and recombinant (folitropin and folitropin + lutropin) gonadotropin preparations on the hormone levels were evaluated. These findings suggest that gonadotropin drugs containing high concentrations of FSH and LH may interfere with routine immunoassay-based hormone tests, leading to errors in clinical interpretation. This study emphasizes the need for careful interpretation of hormone assays in patients undergoing in vitro fertilization treatment, and the importance of considering possible interference effects."

Journal • Gynecology • Infertility • Sexual Disorders

Development of a Dual-Modal PET/NIR-II Probe of Urofollitropin for Enhanced Follicle-Stimulating Hormone Receptor-Targeted Imaging in Diverse Tumors. (PubMed, Mol Pharm) - "The same fluorescence signal intensity trend in diverse tumors was found in the NIR-II images, which was consistent with the FSHR expression detected by Western blotting. Both in vitro and in vivo assays showed the specific FSHR-targeting capability of 64Cu-NODAGA-uFSH-CH1055 in diverse tumors, indicating that the uFSH-based dual-modal probe has the potential for the noninvasive visualization of various tumors through PET/CT and NIR-II imaging."

Journal • Endocrine Disorders • Infertility • Oncology • Sexual Disorders

The Type of Follicle-Stimulating Hormone Medication Given for In Vitro Fertilization Impacts Oocyte Retrieval: A Systematic Review and Meta-Analysis. (PubMed, Clin Pharmacol Ther) - "Databases were searched from inception to November 2024, including studies that compared two follicle-stimulating hormone medications, including follitropin alfa, follitropin beta, follitropin delta, and urofollitropin...Fertilization, pregnancy, and live birth rates were similar across the medications, despite differences in the number of retrieved oocytes. Additional research is required to evaluate oocyte quality across follicle-stimulating hormone medications."

Journal • Preclinical • Retrospective data • Review • Gynecology

Gonadotropins for ovulation induction in women with polycystic ovary syndrome. (PubMed, Cochrane Database Syst Rev) - "There may be little or no difference in live birth, multiple pregnancy, clinical pregnancy, or miscarriage rates between rFSH and uFSH in women with PCOS. For HMG versus uFSH, we are uncertain whether one or the other improves or lowers rates of live birth, multiple pregnancy, clinical pregnancy, or miscarriage. We are uncertain whether any of the interventions reduce ectopic pregnancy or the incidence of OHSS. In women with clomiphene citrate failure, gonadotropins (FSH) probably result in more live births and clinical pregnancies than continued clomiphene citrate without increasing multiple pregnancies. Gonadotropins may increase the miscarriage rate per woman. We are uncertain if gonadotropins reduce ectopic pregnancy. None of the women developed OHSS."

Clinical • Journal • Review • Gynecology • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - P=N/A | N=810 | Completed | Sponsor: Lund University | Phase classification: P4 ➔ P=N/A | Trial completion date: Jun 2024 ➔ Oct 2024

Phase classification • Trial completion date • Gynecology • Infertility • Sexual Disorders

HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - P4 | N=796 | Completed | Sponsor: Lund University | Trial completion date: Dec 2020 ➔ May 2024

Adverse events • Biomarker • Trial completion date • Gynecology • Infertility • Sexual Disorders

Clinical efficacy of Xuanju compound capsule combined with urofollitropin in the treatment of patients with idiopathic oligoasthenozoospermia (PubMed, Zhonghua Nan Ke Xue) - "Xuanju compound capsule combined with urofollitropin tablets could significantly improve the semen quality, up-regulate the testosterone levels and T/E2 ratio in patients with idiopathic oligoasthenozoospermia."

Journal

Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study. (PubMed, Gynecol Obstet Invest) - "The standard of care for OS cycles is described with respect to IVF/ICSI treatment including an LH component in Germany during the specified timeframe."

Journal • Gynecology • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins (ENDO 2023) - "Group A was treated with gonadotropins [urofollitropin 150 IU three times a week and human chorionic gonadotropin (hCG) 2000 IU twice a week], Group B with liraglutide (3 mg daily), and Group C with transdermal testosterone (60 mg daily). Liraglutide is an effective weight loss drug, which also improves serum gonadotropin and total testosterone levels, sperm conventional parameters, and sexual function in obese patients with functional hypogonadism seeking parenthood. This is the first study documenting the efficacy of liraglutide on the testicular function of these patients.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins."

Clinical • Endocrine Disorders • Infertility • Metabolic Disorders • Obesity • Sexual Disorders

Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. (PubMed, J Clin Med) - "Group A patients were treated with gonadotropins (urofollitropin at 150 IU, three times a week, and human chorionic gonadotropin at 2000 IU, twice a week), Group B patients with liraglutide (3 mg daily), and Group C patients with transdermal testosterone (60 mg per day). Liraglutide has also shown advantages over traditional treatments on both reproductive and sexual function and appears to offer greater benefits in terms of metabolic protection. These findings suggest that liraglutide is a useful drug for the treatment of obese males with metabolic hypogonadism."

Journal • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity

The İmpact of Gonadotropin Type on Controlled Ovarian Stimulation and İntrauterine İnsemination Cycle Outcomes. (PubMed, J Hum Reprod Sci) - "Eligible cycles were divided into three groups according to the type of gonadotropin used for COS; cycles with recombinant follicle-stimulating hormone (rFSH) (group 1, n = 36), highly purified FSH (HP-FSH) (group 2, n = 178) and highly purified menotropin (HP-hMG) (group 3, n = 23)...Furthermore, these three gonadotropin protocols for COS + IUI yielded comparable CPR and LBR. These findings suggest that all three gonadotropin types (rFSH, HP-FSH, HP-hMG) are similarly effective in COS + IUI cycles."

Journal • Infertility • Sexual Disorders

HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - P4 | N=796 | Completed | Sponsor: Lund University | Recruiting ➔ Completed

Adverse events • Biomarker • Trial completion • Gynecology • Infertility • Sexual Disorders

[VIRTUAL] Good cumulative clinical pregnancy rates in PGT-M with trophectoderm biopsy (Fertility 2021) - "Follitropin alfa was used for stimulation for all cases except 3 who had Urofollitropin...Despite variations to stimulation strategies, no clear way of reducing this was identified. The current treatment pathway does not appear to be detrimental to CPR."

Clinical • Genetic Disorders

Letrozole Versus Gonadotropins in Clomiphene Citrate Resistance (clinicaltrials.gov) - P4; N=70; Completed; Sponsor: Tanta University

New P4 trial

HEART: Hormone Evaluation in Artificial Reproductive Technology (clinicaltrials.gov) - P4; N=890; Recruiting; Sponsor: Lund University; Trial primary completion date: Jun 2021 ➔ Dec 2020

Adverse events • Biomarker • Clinical • Trial primary completion date • Gynecology • Infertility • Sexual Disorders

"In vitro" Effect of Different Follicle-Stimulating Hormone Preparations on Sertoli Cells: Toward a Personalized Treatment for Male Infertility. (PubMed, Front Endocrinol (Lausanne)) - "We analyzed the effects of different FSH preparations (α-follitropin, β-follitropin, and urofollitropin) in combination with testosterone on porcine pre-pubertal Sertoli cells...Surprisingly, the combination of testosterone with β-follitropin specifically induced an up-regulation of eight specific secreted proteins. Our study, showing that the three different FSH preparations induce different effects, could offer the opportunity to shed light inside new applications to a personalized reproductive medicine."

Journal • Preclinical • Infertility • Sexual Disorders

[VIRTUAL] In Vitro Effect of Different Follicle-Stimulating Hormone Preparations on Sertoli Cells (ENDO-I 2020) - "All preparations induced an increase in the secreted inhibin beta A chain, but in the medium after stimulation with urofollitropin we observed an higher increase in the levels of this protein. β-follitropin, associated with testosterone, specifically induces an up-regulation of 8 specific secreted proteins.Our study, showing that the three FSH preparations were associated with different effects, could offer the opportunity to shed light inside applications to personalized reproductive medicine."

Preclinical • INHBA

Follicle-Stimulating Hormone Treatment and Male Idiopathic Infertility: Effects on Sperm Parameters and Oxidative Stress Indices according to FSHR c. 2039 A/G and c. -29 G/A Genotypes. (PubMed, J Clin Med) - "The aim of this study was to evaluate the effects of highly purified urofollitropin (hpFSH) on conventional and bio-functional sperm parameters and on oxidative stress indices in patients with idiopathic infertility...The FSHR c. 2039 and FSHR -29 G/A genotypes and allelic distribution did not differ between responders and non-responders. FSH showed to be capable of ameliorating sperm parameters in about half patients treated, therefore it may be helpful in patients with idiopathic infertility."

Journal • Infertility • Sexual Disorders

Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility (clinicaltrials.gov) - P3; N=108; Completed; Sponsor: Benha University

New P3 trial • Biosimilar

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - P1/2; N=30; Not yet recruiting; Sponsor: Center for Human Reproduction

New P1/2 trial • Biosimilar • Growth Hormone • Oncology

Testosterone levels after treatment with urofollitropin in infertile patients with idiopathic mild reduction of testicular volume. (PubMed, Endocrine) - "Reduced TV may predispose to infertility and hypogonadism. FSH treatment may improve Sertoli and Leydig cell function and prevent the development of hypogonadism."

Clinical • Journal • Infertility

Gonadotropin Treatment For The Male Hypogonadotropic Hypogonadism. (PubMed, Curr Pharm Des) - "When gonadotropins are the choice of treatment conventional therapy includes human chorionic gonadotropin (hCG) along with different FSH formulation: human menopausal gonadotropins (hMG), highly purified urinary FSH preparations (hpFSH) (e.g., urofollitropin) or recombinant FSH (rFSH)...Reversal of hypogonadism can occur in up to 10% of patients but its physiophatologic mechanism has yet to be elucidated. In conclusion, gonadotropins therapy is effective in promoting puberty and in supporting spermatogenesis onset and preservation in HH patients with either hypothalamic or pituitary conditions."

Journal • Sexual Disorders

A prospective, randomized study comparing morning to evening administration of gonadotropins in ART. (PubMed, J Assist Reprod Genet) - "AM administration of gonadotropins may be associated with a better ART outcome compared to PM administration. Larger studies are needed to confirm our findings."

Clinical • Journal • Biosimilar • Long-acting Reversible Contraceptives

In Vitro Effect of Different Follicle-Stimulating Hormone Preparations on Sertoli Cells (ENDO 2020) - "All preparations induced an increase in the secreted inhibin beta A chain, but in the medium after stimulation with urofollitropin we observed an higher increase in the levels of this protein. β-follitropin, associated with testosterone, specifically induces an up-regulation of 8 specific secreted proteins.Our study, showing that the three FSH preparations were associated with different effects, could offer the opportunity to shed light inside applications to personalized reproductive medicine."

Preclinical • INHBA

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF (clinicaltrials.gov) - P1/2; N=30; Enrolling by invitation; Sponsor: Center for Human Reproduction; Trial completion date: Jun 2019 ➔ Jun 2022; Trial primary completion date: Jun 2018 ➔ Jun 2021

Trial completion date • Trial primary completion date